Drugmaker Natco Pharma has signed a pact with Switzerland-based Chemo Sa Lugano to source and sell bio-generic products in India and other Asian countries. The pact allows Natco to source four monoclonal antibodies (mAbs) from the Mabxience, a unit of Chemo Sa Lugano, and use them for manufacturing and commercialising finished dosages. Of the four products, three are cancer treatment molecules and one is used in the treatment of auto-immune diseases. Monoclonal antibodies is a highly innovative market globally valued at about Rs 17,250 crore ($35 billion) with insignificant presence of generic products. With the product combinations chosen by Natco, the mAb initiative is likely to be completed over a period of 24-36 months.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: